The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2023
Filed:
Jun. 22, 2017
Applicant:
Crispr Therapeutics Ag, Zug, CH;
Inventors:
Ante Sven Lundberg, Cambridge, MA (US);
Samarth Kulkarni, Cambridge, MA (US);
Lawrence Klein, Cambridge, MA (US);
Hari Kumar Padmanabhan, Cambridge, MA (US);
Assignee:
CRISPR THERAPEUTICS AG, Zug, CH;
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/90 (2006.01); C12N 15/11 (2006.01); C12N 9/22 (2006.01); C07K 14/47 (2006.01); C12N 15/113 (2010.01); A61P 25/28 (2006.01); A61K 35/30 (2015.01); C12N 5/0793 (2010.01); C12N 5/079 (2010.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 35/30 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); A61P 25/28 (2018.01); C07K 14/47 (2013.01); C12N 5/0619 (2013.01); C12N 5/0622 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/907 (2013.01); C12Y 301/21001 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract
The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.